Linaclotide
From Pharmacopedia
More actions
Linaclotide
Linzess
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
IBS with predominant constipation0, Chronic idiopathic constipation0, Functional constipation in pediatric patients 6-17 years0
Pharmacy
Starting dose
145 mcg PO once daily for chronic idiopathic constipation; 290 mcg daily for IBS-C; pediatric 72 mcg daily
Preparations
72, 145, 290 mcg capsules
US FDA Max
290 mcg/d
Pharmacology
Routes
Oral
Onset
Bowel movement within 1 week; abdominal pain improvement over weeks
Duration
24 hours
Half-life
Not meaningfully described (negligible systemic absorption — the drug acts locally and is degraded in the GI tract)[1]
Bioavailability
Negligible systemic absorption[1]
Pregnancy
Limited data; minimal systemic absorption likely renders fetal risk low.[citation needed]
Legal status
Purported mechanism
Linaclotide is a 14-amino-acid peptide agonist of guanylate cyclase-C (GC-C) on the luminal surface of intestinal epithelial cells; receptor activation raises intracellular and extracellular cGMP, which opens the CFTR chloride channel and increases chloride/bicarbonate secretion (and consequently water) into the gut lumen, accelerating transit.0 Extracellular cGMP separately activates submucosal sensory afferents in a way that reduces visceral pain perception, distinguishing linaclotide from purely osmotic laxatives in IBS-C. Diarrhea is the dose-limiting effect[1].
References
- ↑ 1.0 1.1 1.2 1.3 FDA Prescribing Information, Linzess (linaclotide), AbbVie/Ironwood, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202811s011lbl.pdf